Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03970278 · ClinicalTrials.gov registry record
Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia
A clinical trial of Glycogen Storage Disease Type Ia and Von Gierke's Disease (GSD Type Ia), sponsored by Ultragenyx Pharmaceutical.
- Completed
- Registry status
- 12
- Enrollment target
- 6
- Study locations
NCT03970278 is a study of Glycogen Storage Disease Type Ia and Von Gierke's Disease (GSD Type Ia) that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 12 participants, below the 49-participant average among 5 other Glycogen Storage Disease Type Ia trials with a reported enrollment target (76% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT03970278, a study of Glycogen Storage Disease Type Ia and Von Gierke's Disease (GSD Type Ia), has completed, sponsored by Ultragenyx Pharmaceutical.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary objective of this study is to determine the long-term safety of DTX401 following a single intravenous (IV) dose in adults with GSDIa.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (6)
Connecticut
- UCONN Health - Farmington
Michigan
- Michigan Medicine University of Michigan - Ann Arbor
Texas
- University of Texas Health Science Center at Houston - Houston
Quebec
- Montreal Children Hospital, McGill University Health Centre - Montreal
Other
- University Medical Center Groningen - Groningen
A Coruna
- Complejo Hospitalario Universitario de Santiago - Santiago de Compostela
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2025-02-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03970278
The ClinicalTrials.gov registry entry for NCT03970278 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 49-participant average among 5 other Glycogen Storage Disease Type Ia trials with a reported enrollment target (76% lower). The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glycogen Storage Disease Type Ia appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT03970278 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Connecticut, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT03970278 about?
NCT03970278 is a clinical study titled "Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia". The primary objective of this study is to determine the long-term safety of DTX401 following a single intravenous (IV) dose in adults with GSDIa.
What is the current status of trial NCT03970278?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2019-07-15. Estimated completion is 2025-02-25.
What conditions does trial NCT03970278 study?
This clinical trial studies the following conditions: Glycogen Storage Disease Type Ia, Von Gierke's Disease (GSD Type Ia).
What interventions are being tested in trial NCT03970278?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT03970278?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03970278 being conducted?
This trial has 6 study locations across Connecticut, Michigan, Texas, Quebec, A Coruna. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glycogen Storage Disease Type Ia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accuracy of Lactate Meter in GSDIa
RECRUITING
-
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
RECRUITING · Phase 1
-
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
RECRUITING
-
Accuracy of Home Lactate Meter and Accu-chek Glucometer in Patients With Glycogen Storage Disease
RECRUITING
-
A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)
COMPLETED · Phase 3
Explore more on PlainTrial
Glycogen Storage Disease Type Ia
All registered trials for this condition
Von Gierke's Disease (GSD Type Ia)
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.